Brief: Alzamend Receives Pre-IND Response From FDA For AL001 Treatment Of Bipolar Disorder, MDD, PTSD
Alzamend Neuro gets positive FDA feedback on development of lead drug
Brief: Alzamend Neuro Announces Pre-IND Submission for AL001 As Treatment of 3 Disorders
Brief: Alzamend Neuro Announces Initiation Of Phase IIA Multiple Ascending Dose Clinical Trial For AL001 Treatment Of Dementia Related To Alzheimer’S
Brief: Bitnile Holdings Announces Additional Investment In Alzamend
Brief: Alzamend Neuro Announces $4 Mln Additional Investment From Digital Power Lending
Brief: Alzamend Neuro Signs Contracts With Altasciences And Iresearch Atlanta
Brief: Alzamend Neuro Announces Full Data Set From Phase 1 First-In-Human Clinical Trial For Al001 Treatment Of Dementia Related To Alzheimer's
U.S. RESEARCH ROUNDUP-Apellis Pharmaceuticals, ONEOK, Progressive
Brief: Alzamend Neuro Announces Positive Topline Data From Phase 1 First-In-Human Clinical Trial For AL001 Treatment Of Dementia Related To Alzheimer's
U.S. STOCKS ON THE MOVE-Roblox, CMC Materials, Eli Lilly, energy stocks
Brief: Alzamend Neuro Announces Date For Delivery Of Topline Data For Phase 1 First-In-Human Clinical Trial For Al001 For Dementia Related To Alzheimer's
U.S. STOCKS ON THE MOVE-Zoom, Gap Inc, Chevron
U.S. STOCKS ON THE MOVE-Zoom, Tesla, Chevron
Alzamend Neuro rises after founder buys over 19,000 shares
U.S. RESEARCH ROUNDUP-Acceleron pharma, Five9, Silgan Holdings
U.S. STOCKS ON THE MOVE-EA, Carmax, U.S. department stores
Alzamend surges after FDA clears clinical trial for Alzheimer's disease drug
NASDAQ RESUMED AT 10:21 AM